市場調查報告書
商品編碼
927868

梅毒快速血漿反應素試驗(RPR)全球市場:成長、趨勢、預測(2020年∼2025年)

Rapid Plasma Reagin Test Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

預估全球梅毒快速血漿反應素試驗市場於2020年至2025年將以4.1%的CAGR推移。 快速血漿反應素試驗使用於檢測梅毒、梅毒螺旋體所引起的性傳染病。梅毒的初期症狀包含發燒、腺體腫脹、肌肉疼痛、皮疹、喉嚨痛等。此外,梅毒初期階段的人可能會有傷口或病變,這些在性接觸過程中可能會傳染給其他人。梅毒未被檢測出時會停留在體內數年,並且可能損害內臟。隨著時間經過,可能導致麻痺、失明、麻木、甚至死亡。梅毒若能於早期診斷出將可治癒,這大幅增加了適切且即時診斷的重要性。

根據 Current Epidemiology Reports 2018 發表的研究,全球每年約有600萬的梅毒新病例。超過300,000的胎兒及新生兒因梅毒死亡,約215,000的嬰兒因梅毒而有早期死亡危險。該市場主要推動因素包含梅毒罹病率增加、對性傳染病的認知提升、技術進步、快速血漿反應素試驗的新產品推出等。

本報告研究全球梅毒快速血漿反應素試驗(RPR)市場,綜合性彙整市場概要、按產品及區域的市場規模推移和預測、市場趨勢、市場成長及阻礙因素分析、市場機會、競爭情勢、主要企業簡介等情報。

第1章 前言

第2章 研究方法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長因素
    • 梅毒罹病率增加
    • 快速血漿反應素試驗的技術進步
    • 性傳染病罹患率相關認知提升
  • 市場阻礙因素
    • 不完善的償付方針
    • 發展中國家的疾病篩檢相關採用缺乏
  • 波特五力分析

第5章 市場區分

  • 按產品類型
    • 檢測套組
    • 測定儀器
    • 試劑
  • 按末端使用者
    • 醫院和診所
    • 診斷實驗室
    • 其他
  • 按區域
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲地區
    • 南美

第6章 競爭情勢

  • 企業簡介
    • Cardinal Health, Inc
    • Thermo Fisher Scientific
    • Abbott Laboratories (Alere)
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories
    • Siemens Healthcare
    • AccuBioTech Co.,Ltd
    • Becton Dickinson and Company
    • Danaher Corporation (Beckman Coulter Inc)
    • bioLytical Laboratories Inc

第7章 市場機會與未來趨勢

目錄
Product Code: 68313

The rapid plasma reagin test market is expected to register a CAGR of 4.1% during the forecast period. The rapid plasma reagin (RPR) test is a serological test that is used to screen for syphilis, a sexually transmitted infection caused by spirochete bacterium treponema pallidum. Symptoms of syphilis are common to many other illnesses. Some of the early symptoms include fever, swollen glands, muscle aches, rash, and sore throat. Moreover, people who have early-stage syphilis may have sores or lesions, and these can pass the infection on to other people during sexual contact. If syphilis is not detected, it can stay in the body for many years and can harm internal organs. Over time it can cause paralysis, blindness, numbness, and even death. Syphilis can be cured if it is diagnosed in the early stages; this significantly increases the importance of proper and timely diagnostics.

As per the study published in the Current Epidemiology Reports 2018, every year, around 6 million new cases of syphilis were observed in persons aged 15 to 49 years globally. In addition, over 300,000 fetal and neonatal deaths were due to syphilis, and nearly 215,000 infants are at risk of early death due to syphilis.

Increasing incidence of syphilis, growing awareness for sexually transmitted diseases and technological advancement, and the launch of the new products for rapid plasma reagin testing are the key driving factors in the rapid plasma reagin test market.

Key Market Trends

The Rapid Plasma Reagin Test Kits Segment is Expected to Hold a Major Market Share in the Rapid Plasma Reagin Test Market

  • Rapid plasma reagin test kits are used for the qualitative and semi-quantitative determination of reagin antibodies in serum or plasma from persons with syphilis.
  • According to the World Health Organization (WHO), more than 1 million sexually transmitted infections (STIs) are acquired every day globally. Moreover, in 2016, about 9,88,000 pregnant women were infected with syphilis resulting in over 3,50,000 adverse birth outcomes, including 2,00,000 stillbirths and newborn deaths.
  • Rapid plasma reagin test kits segment holds a significant market share in the rapid plasma reagin test market and is anticipated to show a similar trend over the forecast period due to the high usage of assays, and the growing availability of the test kits.
  • Increasing incidence of sexually transmitted diseases, including syphilis, and technological advancement in rapid plasma reagin testing are the key driving factors in the rapid plasma reagin test kits segment.

North America is Expected to Hold a Significant Share in the Market during the Forecast Period

North America is expected to hold a major market share in the global rapid plasma reagin test market due to the increasing incidence of sexually transmitted diseases, including syphilis, and growing awareness regarding the morbidity of sexually transmitted diseases in this region. According to the Centers for Disease Control and Prevention (CDC), in the year 2017, about 30,644 cases of primary and secondary (P&S) syphilis were reported in the United States, i.e., 9.5 cases per 100,000 population which represents a 10.5% increase compared with the year 2016 (8.6 cases per 100,000 population), and a 72.7% increase compared with the year 2013 (5.5 cases per 100,000 population). Furthermore, technological advancement and the launch of new products, high healthcare spending, and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The rapid plasma reagin test market is moderately fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Cardinal Health Inc., Thermo Fisher Scientific, Abbott Laboratories (Alere), F. Hoffmann-La Roche Ltd, Danaher Corporation (Beckman Coulter Inc.), Siemens Healthcare, AccuBioTech Co. Ltd, Becton Dickinson and Company, Bio-Rad Laboratories, and bioLytical Laboratories Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Syphilis
    • 4.2.2 Technological Advancement in Rapid Plasma Reagin Testing
    • 4.2.3 Growing Awareness Regarding the Morbidity of Sexually Transmitted Diseases
  • 4.3 Market Restraints
    • 4.3.1 Poor Reimbursement Policies
    • 4.3.2 Lack of Adoption Regarding Disease Screening in Developing Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Rapid Plasma Reagin Test Kits
    • 5.1.2 Analyzers and Instruments
    • 5.1.3 Reagents
  • 5.2 By End User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Diagnostic Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Cardinal Health Inc.
    • 6.1.2 Thermo Fisher Scientific
    • 6.1.3 Abbott Laboratories (Alere)
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Bio-Rad Laboratories
    • 6.1.6 Siemens Healthcare
    • 6.1.7 AccuBioTech Co. Ltd
    • 6.1.8 Becton Dickinson and Company
    • 6.1.9 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.10 bioLytical Laboratories Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS